Alexander J. Valvezan

This paper identifies IMPDH as a therapeutic target in PTEN-deficient T-ALL, showing IMPDH inhibitors selectively kill these cells and extend survival in mouse models.

This study shows ATR enhances mTORC1 activity through cholesterol synthesis via LSS, independent of CHK1 and TSC, and this effect is amplified in p16-deficient cells.

This study shows mTORC1 activity oscillates during the cell cycle, peaks in S and G2, and is lowest in mitosis and G1, with distinct regulatory mechanisms and functional consequences.